Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Cancer. 2002 Aug 15;95(4):751-7. doi: 10.1002/cncr.10762. Cancer. 2002. PMID: 12209718 Free article. Clinical Trial.
Pemetrexed in bladder, head and neck, and cervical cancers.
Paz-Ares L, Ciruelos E, García-Carbonero R, Castellano D, Lopez-Martín A, Cortés-Funes H. Paz-Ares L, et al. Semin Oncol. 2002 Dec;29(6 Suppl 18):69-75. doi: 10.1053/sonc.2002.37476. Semin Oncol. 2002. PMID: 12571815 Review.
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Leighl NB, et al. J Clin Oncol. 2005 Apr 20;23(12):2831-9. doi: 10.1200/JCO.2005.04.044. J Clin Oncol. 2005. PMID: 15837997 Clinical Trial.
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Paz-Ares L, et al. J Clin Oncol. 2006 Mar 20;24(9):1428-34. doi: 10.1200/JCO.2005.04.3299. J Clin Oncol. 2006. PMID: 16549837 Clinical Trial.
Prognostic value of KIT expression in small cell lung cancer.
López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, Sánchez-Cespedes M, Castellano D, Bartolomé A, Cortés-Funes H, Paz-Ares L. López-Martin A, et al. Lung Cancer. 2007 Jun;56(3):405-13. doi: 10.1016/j.lungcan.2007.01.029. Epub 2007 Apr 8. Lung Cancer. 2007. PMID: 17420067
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Cobo M, et al. J Clin Oncol. 2007 Jul 1;25(19):2747-54. doi: 10.1200/JCO.2006.09.7915. J Clin Oncol. 2007. PMID: 17602080 Clinical Trial.
457 results